EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)^[1] .

EMI1 inhibits PC9 EGFR ex19del/T790M/C797S organoid growth with the EC₅₀ of 131 nM^[1] .
EMI1 (1 nM-10 μM) potently reduces the interaction of EGFR triple mutant with Shc1^[1] .
EMI1 (1 nM-100μM) strongly inhibits the viability and increase the caspase 3/7 activity of PC9 EGFR ex19del/T790M/C797S triple-mutant cells than noncancerous human bronchial epithelial (HBE) cells^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

334.37

C??H??N?O?

35773-42-3

O=C1C(C2=NC3=CC=CC=C3O2)=CC4=CC=C(N(CC)CC)C=C4O1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Punit Saraon, et al. A drug discovery platform to identify compounds that inhibit EGFR triple mutants. Nat Chem Biol. 2020 May;16(5):577-586.